We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 10,862.00 | 10,902.00 | 10,906.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 28.38 | 169.03B |
Date | Subject | Author | Discuss |
---|---|---|---|
15/11/2021 08:42 | Closed out Friday's trade. | essentialinvestor | |
13/11/2021 20:26 | So they’re back to where they were a few weeks ago? | wish i wasnt in rbs | |
13/11/2021 16:50 | We have seen some significant drops in recent months although not by as much as this one, however each has more often than not been followed by a strong recovery within a few days or so. | bountyhunter | |
13/11/2021 12:19 | I agree, the drop seems unjustified and appears to be largely due to all the fuss about the Covid vaccine not moving into profit as quickly or by as much as some may have anticipated. I know it's easy to say after an unexpected drop like this but I don't see anything in the fundamentals that will justify this drop being maintained or worsening. One to hold now until the dust has settled and normal service is resumed imho. I must confess I was caught out by the drop fully expecting the opposite especially after the positive signs heading into results. I won't eat my hat if there is not a decent bounce back on Monday as that would be tempting fate but I do expect at least a partial recovery progressively moving back up from here, but wtfdik! Fortunately I also hold GSK which has surpassed my expectations and pays a generous dividend to boot! The Motley Fool is bullish on AZN post results... "...the latest results were positive. Revenue for the quarter came in at $9.9bn, an increase of 48% versus the same period last year. This was driven in part thanks to the acquisition and integration of Alexion. Even with this, good percentage growth was seen across multiple segments from a year-to-date perspective. Product sales were up 29%, oncology division revenue was up 16% and CVRM revenue was up 10%. These drivers should allow the company to meet the full-year guidance provided earlier this year. In terms of risks, the business noted that Covid-19 is still going to cause issues. When commenting on the virus impact, it said that “variations in performance between quarters can be expected to continue”. | bountyhunter | |
13/11/2021 12:09 | I thought results rather good? Sell off the C-19 stuff, I continue to see no takers. One notices that GSK (I'm a holder) flying, not sure why. | dudishes | |
12/11/2021 22:17 | John Nada12 Nov '21 - 21:27 - 5085 of 5085 (Filtered) Nada = Nothing! | gateside | |
12/11/2021 21:27 | 'awful pandemic' So awful overall death rate doesn't rise during the supposed running wild but shoots up 20% when the jab is introduced. But facts means nothing now because it's 'the science'. Facts are immaterial in the face of 'the science'. But the removal of drug trial participants from said trial who suffer horrific side effects is perfectly acceptable and their accounts are striken from the record as if she never existed. Oh the MRHA call the gene therapy shots robustly tested. LMFAO. The same jab regulator that receives huge sums of money from Bill Gates. | john nada | |
12/11/2021 20:33 | >>AstraZeneca cannot play missionary worker forever Totally agree, half the price of Pfizer's vaccine with no dry ice required would still be a market leading profits enhancing proposition. Astra's time will come in the endemic stage and history will view the Oxford vaccine as playing a major role in overcoming this pandemic globally. Poorer countries cannot afford Pfizer's expensive vaccine or orchestrate the expensive logistics required which is where the at cost Oxford vaccine from Astra is playing a major role in overcoming this awful pandemic. | bountyhunter | |
12/11/2021 20:27 | 5086 (Filtered) | bountyhunter | |
12/11/2021 19:17 | You'd think the group that would jump at the chance to take the life saving AZN jab would be the care home staff after seeing their inmates dropping like flies from this 'killer virus' which must be true because the pcr tests are infallible. OK the liverpool care pathway and Midazolan and the deliberate starvation and dehydration may have had something to do with it. Surely they'd have seen the amazing result of their patients being vaccinated. I mean deaths in the U.K have gone up 20% against the five year average the last few months when they were level throughout the 'pandemic (nudge nudge) last year but that's just a coincidence right. 60K care home staff who'd rather go and lose their livelihood. It just doesn't make any sense does it AZN shareholders. What gives? | john nada | |
12/11/2021 18:35 | AstraZeneca cannot play missionary worker forever There is plenty of good that can come from the pharma giant's decision to start making a 'modest profit' from its Covid vaccine BEN MARLOW CHIEF CITY COMMENTATOR 12 November 2021 • 5:45pm Ben Marlow Hero or villain? It says much about the bitterness of some European leaders that Pascal Soriot was ever cast as the latter during the pandemic. The vilification of AstraZeneca’s chief executive was a sordid moment in the crisis, another serious blow to recently formed post-Brexit relations, as the likes of President Macron sought to deflect from mounting criticism at home for the way that France had fallen badly behind in the race to inoculate its people. Soriot will be remembered by fair-minded people as one of the standout champions of the crisis for the courage and leadership he displayed in providing the company’s unequivocal backing for Oxford University’s experimental Covid vaccine. He showed total faith in Professor Sarah Gilbert in agreeing to provide the commercial and manufacturing heft needed to turbocharge development of the AZD1222 jab and bring it to market in time to save untold numbers of lives. And what’s more, it pledged to do so at cost, effectively providing a humanitarian service to the world. So imagine the faux-outrage in some quarters from AstraZeneca’s sour opponents after the FTSE 100 drugmaker announced plans to make a modest profit from future sales of the coronavirus jab. The naysayers should save their breath. Having already produced something like 1bn jabs effectively for free, the company is surely entitled to monetise the programme at some point, and why not now? Although the virus is still prevalent in many parts of the world, rapid inoculation has turned the fight on its head. Covid-19 is no longer the threat that it once was. The health emergency has passed and most developed countries at least are rightly trying to live with it. A few zero-Covid outliers remain, but they are on the wane. Even the high priest of lockdown, New Zealand prime minister Jacinda Ahern, has been forced to concede that the virus can never be contained, and any attempts to do so would be economically ruinous. China will discover this too in the coming months, with serious consequences for the rest of the world, unless it sharply changes tack. More: | maxk | |
12/11/2021 18:32 | AstraZeneca to start making a profit from Covid jab as virus becomes ‘endemic&rsquo The company argues Covid is becoming endemic, justifying its decision to start profiting from its vaccine By Hannah Boland 12 November 2021 • 3:14pm AstraZeneca is to start taking a profit from its Covid jab in a sign that one of the world's biggest drugmakers believes the pandemic is at an end. The pharmaceutical company said that coronavirus is becoming endemic and a pledge to deliver its vaccine at cost price is no longer needed. Astra's chief executive Pascal Soriot urged countries to accept that coronavirus will continue to circulate in a similar way to flu as life returns to normal. He said: "We did actually start this project to help, but we also said that at some stage in the future, we will transition to commercial orders. "The virus is becoming endemic and we have to learn to live with it." Experts believe Britain is on the cusp of endemicity - where infection levels are relatively stable rather than surging in massive waves - after cases steadily declined in the absence of restrictions this month. Other European countries such as Austria and Germany are experiencing sharp rises, but are thought likely to reach endemicity within months. More: | maxk | |
12/11/2021 18:13 | Just use the filter button guys.Then you don't have to read what any nutcase says! | gateside | |
12/11/2021 17:59 | John, you seem to be fixated on hell . Are you a born again C or a defrocked priest ? | toob | |
12/11/2021 16:45 | www.voxmarkets.co.uk AZN 19:50 | brummy_git | |
12/11/2021 15:59 | A bad case of long Covid? | bountyhunter | |
12/11/2021 15:29 | My my! your medication appears to be failing you, perhaps its a AZN product,no doubt that would confirm your rantings to be correct! | the lockkeeper | |
12/11/2021 15:04 | Alphabet inc google parent company is heavily invested in the plandemic through their lifescience company verily. I also believe they own various covid patents. Filter all you like. Not a single response regarding Brienne Dessen and AZN removing her from the trial AFTER her severe reaction. Not a single response because there cannot be one. AZN should be under investigation but they will never be because this is a giant gravy train. | john nada | |
12/11/2021 14:52 | In for just a small amount. | essentialinvestor | |
12/11/2021 14:40 | They can't justify this high rating on these figures. | montyhedge | |
12/11/2021 14:35 | Just goes to show what little knowledge you have of the pharmaceutical industry if you think it's easy getting a drug onto the market..... But hey John I guess when you get something wrong with you you won't be asking for any tablets because they are made by those big bad pharma companiesYour other post says it all really what a prat.... Of course Google are on board covering the pandemic scam up! .... I think your Google search results are more down to what you look at and ask Google to find.... Try typing Brianne Dressen and you'll get lots of hits but of course it's a cover up by GoogleTry not surfing the porn so much dear John and your search results might be a bit more relevantNot reading anymore of your drivel...Filtered | cgee1 | |
12/11/2021 14:12 | Jeez, I'm going to hell in a handcart. I hold AZN, GSK, IMB and BATS ! | philanderer | |
12/11/2021 14:01 | FWIW 12th nov UBS buy tp 10000p 12th nov Jefferies buy tp 9950p 12th nov JP Morgan overweight tp 10000p Sharecast: IG market analyst Joshua Mahony said: "AstraZeneca has seen little enthusiasm for their plan to shift into a strategy of ‘modest profitability’ for their vaccine product, with the company hoping to strike new deals at a more advantageous price. "Coming off the back of a nine-month period that brought $2.2 billion of vaccine sales, shareholders are clearly looking for the firm to boost the earnings outlook after EPS fell short of expectations." | philanderer |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions